Home > Rights & Freedoms > Ethics in Biotechnology

Ethics in Biotechnology

Human beings in the early stages of their development must not be objects of commercial interests
The Advocate-General of the European Court of Justice in Luxembourg has pleaded to generally exclude human embryos from patentability. Since in most cases the Court follows the Advocate-General in its ruling, the Court will probably decide likewise.

 “I am very glad that we can now expect a decision that human beings in the early stage of their development are not made an object of commercial interests. If the decision was different, human embryos would become the object of exclusive marketing rights of individuals. This would lead to another overstepping of a threshold in the protection of human life”, said Peter Liese MEP, EPP Group Co-coordinator in the Environment, Public Health and Food Safety Committee of the European Parliament.

The German scientist, Professor Oliver Brüstle, whose patent application is the reason for the court case, and whose lawyers have even called for making cloned human embryos (created by the transplantation of genetic information from a body cell into an egg cell) the subject of patents, is also against the Advocate-General’s wishes.

Back in the late 90s, Brüstle had already applied for the patent. It is about the patenting of so-called neural precursor cells. One of the methods for obtaining these cells, the cloning of embryos (Cell Nuclear Transfer), is described in the patent specification. For the production of these cells, embryos have to be destroyed. Thus, for ethical reasons, Greenpeace had raised an objection against the patent. “The underlying 1998 EU Directive contains numerous restrictions on patentability for ethical reasons. This was a sine qua non condition of the European Parliament for the approval of the Directive”, said Peter Liese, who wrote his dissertation at the Institute of Human Genetics at the University of Bonn. The Federal Patent Court essentially decided in favour of Greenpeace; Brüstle then went to the Federal Court of Justice in Germany in order to object to the decision.

The Federal Court of Justice has now referred to the European Court of Justice not the question of how to deal with the patent, but the fundamental question of the patentability of human embryos and the patentability of cells derived from them. The Advocate-General has given the following recommendations: Similarly, the blastocyst stage of development, reached around five days after fertilisation, must also be classified as an embryo, since, according to the Advocate-General, the principle of human dignity, to which the Directive refers, is a principle which must be applied not only to an existing human person, to a child who has been born, but also to the human body from the first stage in its development, i.e. from fertilisation.

In the Advocate-General’s opinion, it must therefore be agreed that inventions relating to pluripotent stem cells can be patentable only if they are not obtained to the detriment of an embryo, be it its destruction or modification.

To make an industrial application of an invention using embryonic stem cells would amount to using human embryos as simple base material, which would be contrary to ethics and public policy. “The Advocate-General’s decision is a major success for all who fight for ethics in modern biotechnology. I hope very much that the ECJ will follow this position. Developments over the last 10 years have shown that the hopes which have been put in embryonic stem cells are far from being realised. Patients benefit much more from alternative branches of research”, Peter Liese said. The final verdict is expected for the summer or autumn of 2011.

  1. June 3, 2011 at 14:52

    Полезно, не съжалявам за последните 10 минути от деня ми, през които четох материала. Поздрави и успех и за напред🙂

  2. August 2, 2011 at 22:07

    I remember the reactions this Advocate General’s opinion caused.

    By the way, you might want to compare it to the very recent and opposite ruling of the US Court of Appeal for the Federal Circuit (http://bit.ly/qbIkly) or read the corresponding analysis on the PatentlyO Blog (http://bit.ly/mZ145L).

    BR,
    Emil

  3. July 12, 2012 at 13:22

    I totally agree that we should not human beings in the early stages of their development should not be subject to commercial interests. At least to keep it clean and not to trade in human life. It is not fair so this is pure mockery and ridicule for me personally. The article is very interesting covers interesting questions that make you think twice as to where

  4. October 20, 2012 at 10:11

    Federal Court of Justice has already indicated to the Court of Justice is not a question of how to deal with a patent, but the fundamental question of patenting and patenting human embryonic cells derived from them. The Advocate General has given the following recommendations and may be followed and expected rezultat.The article is great, very detailed and well written, it was useful to understand some things.

  5. January 13, 2014 at 09:42

    Thank you for sharing valuable information. Nice post. I enjoyed reading this post. The whole blog is very nice found some good stuff and good information here Thanks..Also visit my page pharmaceuticals jobs .

  6. November 29, 2015 at 16:30

    Малко са сигурните и доказани начини човек да изкрава пари от вкъщи по
    интернет. Но все пак има няколко световни сайта, които предлагат подобно нещо.
    Един от тях е UpWork (бившия oDesk). Написа сме няколко статии по темата,
    които се надяваме да ви бъдат
    от полза.

  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: